Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568407 | 0.84 | LTB4R (0.33) | APPCYP3A4CYP2C9AKR1C3AKR1C2 | |
| SCHEMBL3568409 | 0.83 | LTB4R (0.34) | APPCYP3A4CYP2C9AKR1C3AKR1C2 | |
| SCHEMBL3505777 | 0.71 | SRC (0.35) | APPCYP3A4CYP2C9AKR1C3AKR1C2 | |
| SCHEMBL3711502 | 0.70 | HDAC1 (0.42) | APPCYP3A4CYP2C9AKR1C3AKR1C2 | |
| SCHEMBL6685327 | 0.70 | APP (0.42) | APPCYP3A4CYP2C9AKR1C3AKR1C2 | |
| SCHEMBL3575879 | 0.69 | APP (0.40) | APPLMNA | |
| SCHEMBL5040961 | 0.69 | HTR2C (0.47) | ALDH1A1POLB | |
| SCHEMBL3503786 | 0.68 | APP (0.40) | APPCYP3A4CYP2C9AKR1C3AKR1C2 | |
| SCHEMBL10704177 | 0.67 | APP (0.60) | APPCYP3A4CYP2C9AKR1C3AKR1C2 | |
| SCHEMBL21043202 | 0.67 | F10 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772238-B2 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1874295-A4 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090069391-A1 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| EP-1874295-A1 | BENZOTHIOPHENE DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874755-A2 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006115835-A2 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069391-A1 | Benzothiophene hydroxamic acid derivatives | BRDT, HDAC5, BRPF3 | APP 2453/4885CYP3A4 3173/4885CYP2C9 3494/4885 |
| US-20090082308-A1 | Benzothiophene derivatives | BRDT, HDAC5, BRPF3 | APP 2353/4885CYP3A4 2669/4885CYP2C9 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.